Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05522972 · ClinicalTrials.gov registry record · NA

Establishing New Treatment Approaches for Amblyopia: Perceptual Learning and Video Games

A NA study of Amblyopia, sponsored by Nova Southeastern University.

Recruiting
Registry status
NA
Development phase
180
Enrollment target
1
Study location

NCT05522972 is a NA study of Amblyopia that is actively recruiting participants, run by Nova Southeastern University. The registered enrollment target is 180 participants, above the 158-participant average among 24 other Amblyopia trials with a reported enrollment target (14% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05522972, a NA study of Amblyopia, is actively recruiting participants, sponsored by Nova Southeastern University.

RECRUITING
Registry status
NA
Development phase
180 participants
Enrollment target
1
Study location

Study Summary

Amblyopia, a developmental abnormality that impairs spatial vision, is a major cause of vision loss, resulting in reduced visual acuity and reduced sensitivity to contrast. This study uses psychophysical measures to study neural plasticity in both adults and children with amblyopia.

Conditions Studied

Interventions

  • BEHAVIORAL Video Game Vision Training
  • BEHAVIORAL Perceptual Learning
  • BEHAVIORAL Occlusion Therapy

Study Locations (1)

Florida

  • Nova Southeastern University College of Optometry - Fort Lauderdale

Trial Details

FieldValue
Enrollment Target 180 participants
Start Date 2022-09-13
Est. Completion 2029-08-31
Phase NA

Sponsor

Nova Southeastern University

71 total trials

What the Registry Record Tells You About NCT05522972

The ClinicalTrials.gov registry entry for NCT05522972 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 158-participant average among 24 other Amblyopia trials with a reported enrollment target (14% higher). The listed sponsor is Nova Southeastern University, which has 71 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Amblyopia appearing as the primary indexed condition, and to 3 interventions - of which Video Game Vision Training is the first listed.

NCT05522972 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT05522972 about?

NCT05522972 is a clinical study titled "Establishing New Treatment Approaches for Amblyopia: Perceptual Learning and Video Games". Amblyopia, a developmental abnormality that impairs spatial vision, is a major cause of vision loss, resulting in reduced visual acuity and reduced sensitivity to contrast. This study uses psychophysical measures to study neural plasticity in both adults and children with amblyopia.

What is the current status of trial NCT05522972?

This trial is currently recruiting. It is a NA study. The enrollment target is 180 participants. The study started on 2022-09-13. Estimated completion is 2029-08-31.

What conditions does trial NCT05522972 study?

This clinical trial studies the following conditions: Amblyopia.

What interventions are being tested in trial NCT05522972?

The interventions under investigation include: Video Game Vision Training (BEHAVIORAL), Perceptual Learning (BEHAVIORAL), Occlusion Therapy (BEHAVIORAL).

Who is sponsoring clinical trial NCT05522972?

This trial is sponsored by Nova Southeastern University, which has 71 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05522972 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Amblyopia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.